UNSPSC 51273024: Sufentanil citrate

This classification denotes an opioid receptor agonist and opioid with the molecular formula C22H30N2O2S.C6H8O7, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier S9ZFX8403R, chemically known as propanamide, n-(4-(methoxymethyl)-1-(2-(2-thienyl)ethyl)-4-piperidinyl)-n-phenyl- but more generally known as sufentanil citrate, which bears US NIH Compound Identifier 41693. European Medicines Agency schedules Sufentanil citrate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04616MIG.

UNSPSC 51273024 Sufentanil citrate is a Commodity code representing pharmaceutical active ingredients and finished pharmaceutical products procured by state and local health agencies, though recent opportunities suggest the code encompasses a broader pharmaceutical procurement scope including naloxone, generic multi-source drugs, and over-the-counter products. State and local health departments, county public health systems, and multistate cooperative purchasing alliances solicit under this code to support community health programs, emergency medical services, and institutional pharmaceutical supply chains. The work involves competitive bidding and cooperative purchasing vehicles that aggregate demand across multiple jurisdictions, with vendors required to meet FDA compliance, cGMP certification, Drug Supply Chain Security Act (DSCSA) compliance, and comprehensive insurance coverage including commercial general liability and professional liability policies.

Recent activity spans Florida and multistate agreements administered by Minnesota and Texas. Seminole County, Florida issued IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with a response deadline of July 26, 2023. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued RFP S1070000015802 in January 2026 with a March 26, 2026 response deadline for generic multi-source pharmaceuticals and OTC products distributed across participating state and local government facilities including Oregon. The Texas Health and Human Services Commission issued RFI HHS0017013 in April 2026 as an exploratory market-intelligence vehicle to gather vendor capabilities regarding direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager and group purchasing organization arrangements. Vendors must demonstrate relationships with authorized pharmaceutical wholesalers and capacity to fulfill quarterly or ongoing supply obligations with fixed or flexible pricing models and performance penalty provisions.